Differential overall survival (OS) results in RECORD-3 study based on three distinct mRCC molecular subgroups classified by BAP1 and/or PBRM1 mutations.

被引：2

作者：

Hsieh, James

Chen, David

Wang, Patricia

Chen, Yingbei

Marker, Mahtab

Patel, Parul

Chevinsky, Michael

Bhanot, Umesh

Pinciroli, Patrizia

Berger, Michael F.

Cheng, Emily

Lee, William

Knox, Jennifer J.

Voss, Martin Henner

Voi, Maurizio

Motzer, Robert J.

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Novartis Pharmaceut, Global Oncol Dev, E Hanover, NJ USA

[3] Novartis Oncol, E Hanover, NJ USA

[4] Novartis Pharmaceut, E Hanover, NJ USA

[5] Washington Univ, Barnes Jewish Hosp, St Louis, MO USA

[6] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[7] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada

来源：

关键词：

D O I：

10.1200/jco.2016.34.2_suppl.561

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

561

引用

页数：1